Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis

Blood (2025) 146 (Supplement 1): 3664.

https://doi.org/10.1182/blood-2025-3664

Published: 2025

Journal Articles

Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation

Blood (2025) 146 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2025-1763

Published: 2025

Journal Articles

Bulky disease and/or very high LDH define a high-risk LBCL subgroup within IPI 1–2, but only in younger patients

Blood (2025) 146 (Supplement 1): 470.

https://doi.org/10.1182/blood-2025-470

Published: 2025

Journal Articles

Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data

Blood (2025) 146 (Supplement 1): 1834.

https://doi.org/10.1182/blood-2025-1834

Published: 2025

Journal Articles

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 4516.

https://doi.org/10.1182/blood-2025-4516

Published: 2025

Journal Articles

Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort

Blood (2025) 146 (Supplement 1): 3676.

https://doi.org/10.1182/blood-2025-3676

Published: 2025

Journal Articles

FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis

Blood (2025) 146 (Supplement 1): 1826.

https://doi.org/10.1182/blood-2025-1826

Published: 2025

Journal Articles

Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study

Blood (2025) 146 (Supplement 1): 898.

https://doi.org/10.1182/blood-2025-898

Published: 2025

Journal Articles

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

Blood (2025) 146 (Supplement 1): 786.

https://doi.org/10.1182/blood-2025-786

Published: 2025

Journal Articles

Genomic Profiling of Two Successive Post-Transplant Lymphoproliferative Disorders with Different Morphology in a Pediatric Lung Transplant Recipient

Marketa Rackova, Andrea Rennerova, Petr Hubacek, Ester Mejstrikova, Lenka Krskova, Martina Sukova, Marketa Kalinova, Lucie Winkowska, Vit Campr, Tereza Dousova, Lucie Sramkova, Jan Trka, Eva Fronkova

Blood (2024) 144 (Supplement 1): 6192.

https://doi.org/10.1182/blood-2024-209807

Published: 2024

Journal Articles

Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World

Michal Masar, Prokop Vodicka, Samuel Hricko, Andrea Janikova, Katerina Benesova, David Salek, Jana Salkova, Martina Filipova, Jan Galko, Vit Campr, Magdalena Klanova, Marek Trneny

Blood (2024) 144 (Supplement 1): 3081.

https://doi.org/10.1182/blood-2024-208592

Published: 2024

Journal Articles

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

Prokop Vodicka, Andrea Janikova, David Belada, Heidi Mocikova, Vit Prochazka, Juraj Duras, Katerina Steinerova, Vit Campr, Katerina Benesova, Samuel Hricko, Alice Sykorova, Petra Blahovcova, Radek Jaksa, Magdalena Klanova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2023-185620

Published: 2023

Journal Articles

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Prokop Vodicka, Katerina Benesova, Andrea Janikova, David Belada, Heidi Mocikova, Jan Pirnos, Vit Prochazka, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Petra Blahovcova, Vit Campr, Pavel Klener, Jr., Alice Sykorova, Marek Trneny

Blood (2022) 140 (Supplement 1): 3775–3776.

https://doi.org/10.1182/blood-2022-159408

Published: 2022

Journal Articles

Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy

Kamila Polgarova, Andrea Janíková, David Belada, Vit Prochazka, Juraj Ďuraš, Heidi Móciková, Kateřina Steinerová, Vít Campr, Petra Blahovcová, David Zogala, Václav Ptáčník, Marek Trneny

Blood (2022) 140 (Supplement 1): 3831–3832.

https://doi.org/10.1182/blood-2022-163113

Published: 2022

Journal Articles

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Vít K Procházka, Štěpánka Matuštíková, Tomáš Fürst, Dr., David Belada, MD PhD, Andrea Janíková, MD PhD Assoc Prof, Kateřina Benešová, MD PhD, Heidi Mociková, MD, Juraj Ďuraš, MD, Jan Pirnos, MD, Kateřina Kopečková, MD PhD, Vít Campr, MD PhD, Jozef Michalka, MD, Robert Pytlík, MD, Tomáš Papajík, MD prof, Marek Trněný, MD prof

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-139830

Published: 2020

Journal Articles

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

Vit K Prochazka, MD prof, David Belada, MD PhD, Andrea Janikova, MD PhD Assoc Prof, Katerina Benesova, MD PhD, Heidi Mocikova, MD PhD, Juraj Duras, MD, Robert Pytlik, MD PhD, Jan Pirnos, MD, Alice Sýkorová, MD PhD, Vit Campr, MD PhD, Jozef Michalka, MD, Kateřina Kopečková, MD PhD, Jitka Dlouha, Tomas Papajik, MD prof, Marek Trneny, MD prof

Blood (2019) 134 (Supplement_1): 3983.

https://doi.org/10.1182/blood-2019-129756

Published: 2019

Journal Articles

The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Pavel Otahal, MD PhD, Andrea Janikova, MD PhD Assoc Prof, David Belada, MD PhD, Vit Prochazka, MD, Heidi Mocikova, MD PhD, Jan Pirnos, Juraj Ďuraš, Kateřina Kopečková, Vit Campr, MD PhD, Robert Pytlik, Petra Blahovcova, Mgr, Marek Trneny, MD CSc

Blood (2018) 132 (Supplement 1): 5413.

https://doi.org/10.1182/blood-2018-99-117110

Published: 2018

Journal Articles

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Aleš Obr, MD, Vit Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD PhD prof., Pavel Klener, Jr., MD PhD Assoc Prof, Andrea Janikova, MD PhD Assoc Prof, David Salek, MD PhD, David Belada, MD PhD, Robert Pytlik, Alice Sýkorová, MD PhD, Heidi Mocikova, MD PhD, Martin Simkovic, MD PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trněný, MD PhD

Blood (2017) 130 (Supplement 1): 1498.

https://doi.org/10.1182/blood.V130.Suppl_1.1498.1498

Published: 2017

Journal Articles

Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy

Vit K Prochazka, MD PhD Assoc Prof, Tomas Papajik, MD prof., Andrea Janikova, MD PhD, Assoc Prof, David Belada, Tomas Kozak, MD, PhD, Prof., David Salek, MD PhD, Alice Sykorova, MD PhD, Heidi Mocikova, MD, PhD, Vit Campr, MD PhD, Jitka Dlouha, Tomas Fuerst, MSc, PhD, Marek Trneny

Blood (2016) 128 (22): 1779.

https://doi.org/10.1182/blood.V128.22.1779.1779

Published: 2016

Journal Articles

Why Patients with 5q- Syndrome Have Thrombocythemia?

Vit Campr, MD PhD, Jan Stritesky, MD PhD, Ota Fuchs, PhD, Anna Jonasova, MD PhD, Zuzana Zemanova, PhD, Radana Neuwirtova, MD PhD

Blood (2016) 128 (22): 5533.

https://doi.org/10.1182/blood.V128.22.5533.5533

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Improved survival with third-line CAR-T therapy vs alternative treatment in DLBCL: A propensity score–matching analysis

Pre-treatment circulating tumor DNA predicts survival of diffuse large B-cell lymphoma patients and allows genetic and biological evaluation

Bulky disease and/or very high LDH define a high-risk LBCL subgroup within IPI 1–2, but only in younger patients

Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data

Age-stratified prognostic performance of patient- vs disease-related IPI factors in large B-cell lymphoma

Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort

FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis

Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study

Optimizing risk stratification in patients aged 80+ years with large B-cell lymphoma: Comparison of prognostic indices in three pooled international cohorts

Genomic Profiling of Two Successive Post-Transplant Lymphoproliferative Disorders with Different Morphology in a Pediatric Lung Transplant Recipient

Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy

Bayesian Network Modelling As a New Tool in Predicting of the Early Progression of Disease in Follicular Lymphoma Patients

Early Follicular Lymphoma Progression in Patients Treated with Frontline Immunochemotherapy with/without Rituximab Maintenance: Clinically Meaningful Even in Chemosensitive Individuals

The Fate of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Rituximab Maintenance Failure in Mantle Cell Lymphoma Is Associated with High Risk of Death: Analysis of the Czech Lymphoma Study Group (CLSG)

Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy

Why Patients with 5q- Syndrome Have Thrombocythemia?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only